ArticleTurkish journal of biology = Turk biyoloji dergisi2024
Chelidonic acid abrogates oxidative stress and memory dysfunction in experimental aging rats.
Article in Turkish journal of biology = Turk biyoloji dergisi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: In an aging model established using male Wistar albino rats via the administration of D-galactose (D-gal), the aim of this study was to examine the effects of chelidonic acid (CA) on cognitive function and the levels of glutathione (GSH), malondialdehyde (MDA), total antioxidant status (TAS), and brain-derived neurotrophic factor (BDNF). Materials and methods: Thirty-two, three-month-old Wistar albino male rats (n = 8) were divided into four groups, as the control (C) group, CA group (2 mg/kg of CA via oral gavage), D-gal group (150 mg/kg of D-gal, subcutaneously), and D-gal + CA group (150 mg/kg of D-gal and 2 mg/kg of CA). Following overnight fasting, the 10-week trial was concluded with intramuscular injections of anesthetic drugs xylazine (8-10 mg/kg) and ketamine (80-100 mg/kg), and subsequently, the collection of cardiac blood. The brain tissues of the rats were removed. The GSH, MDA, TAS, and BDNF levels were determined in the collected serum samples and prepared tissue homogenates. Novel object recognition and Morris water maze (MWM) experiments were also used to evaluate cognitive function. Results: The D-gal group demonstrated a statistically significant improvement in the discrimination index for memory in both the short and long term compared to the D-gal + CA group. Further analysis of the MWM data for these two groups indicated a notable decrease in the amount of time required for finding the platform. In comparison with the D-gal group, the MDA levels decreased in the CA and D-gal + CA groups, whereas the GSH, TAS, and BDNF levels increased in both the serum and hippocampus samples. Conclusion: CA showed positive effects on age-related neurodegenerative disorders and memory-related processes, especially by increasing TAS and BDNF levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.